Clostridium difficile: Old and new observations

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 1, 2007, Pages

  Bartlett, John G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Pseudomembraneous colitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BACITRACIN; BACTERIAL TOXIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; FUSIDIC ACID; IMMUNOGLOBULIN; MACROLIDE; METHENAMINE MANDELATE; METRONIDAZOLE; NITROFURANTOIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAXIMIN; SULFONAMIDE; TEICOPLANIN; VANCOMYCIN;

AGE DISTRIBUTION; AGING; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; CANADA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG DOSE TITRATION; EPIDEMIC; EUROPE; HOSPITALIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; UNITED STATES;

EID: 34247184821     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31803d16ec     Document Type: Review

References (55)

1. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe Bacillus difficilis. Am J Dis Childhood. 1935;49:390-402.
2. Smith LD, King EO. Occurrence of Clostridium difficile in infections of man. J Bacteriol. 1962;84:65-67.
3. Altemeier WA, Hummel RP, Hill EO. Staphylococcal enterocolitis following antibiotic therapy. Ann Surg. 1963;157:847-858.
4. Khan MY, Hall WH. Staphylococcal enterocolitis - treatment with oral vancomycin. Ann Intern Med. 1966;65:1-8.
5. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974;81:429-433.
6. Bartlett JG, Change TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531-534.
7. Hafiz S, Oakley CL. Clostridium difficile: isolation and characteristics. J Med Microbiol. 1976;9:129-136.
8. al Saif N, Brazier JS. The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol. 1996;45:133-137.
9. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 1981;81:5-9.
10. Tullus K, Aronsson B, Marcus S, et al. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis. 1989;8:390-393.
11. Chang TW. Clostridium difficile toxin and antimicrobial agent-induced diarrhea. J Infect Dis. 1978;137:854-855.
12. McDonald LC, Killgore GE, Thompson A, et al. An epidemic toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
13. Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995;95:2004-2011.
14. Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med. 2001;135:434-438.
15. van den Berg RJ, Claas EC, Oyib DH, et al. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol. 2004;42:1035-1041.
16. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003; a changing pattern of disease severity. CMAJ. 2004;171:466-472.
17. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
18. Miller SD, Koornhof HJ. Clostridium difficile colitis associated with the use of antineoplastic agents. Eur J Clin Microbiol. 1984;3:10-13.
19. Dial S, Delaney JA, Barkum AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA. 2005;294:2989-2995.
20. Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis. 1985;151:476-481.
21. Wistrom J, Noorby SR, Myhre EF, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001;47:43-50.
22. National Clostridium difficile Standards Group. National Clostridium difficile Standards Group: Report to the Department of Health. J Hosp Infect. 2004;56(suppl 1):1-38.
23. Kyne L, Warny M, Qama A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
24. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
25. Verity P, Wilcox MH, Fawley W, et al. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms. J Hosp Infect. 2001;49:204-209.
26. Kim KH, Fekety R, Batts DH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143:42-50.
27. Fawley WN, Wilcox MH. Molecular epidemiology of endemic Clostridium difficile infection. Epidemiol Infect. 2001;126:343-350.
28. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol. 2004;42:1203-1206.
29. Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis. 2002;34:1585-1592.
30. Pepin J, Baliquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037-1042.
31. Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol. 2005;43:2994-2995.
32. Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44:1145-1149.
33. Bartlett JG, Onderdonk AB, Cisneros RL. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology. 1977;73:772-776.
34. Browne RA, Fekety R Jr, Silva J Jr, et al. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J. 1977;141:183-192.
35. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
36. Wenisch C, Parchalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole versus vancomycin for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.
37. Teasley DG, Gerding DN, Olsen MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 1983;2:1043-1046.
38. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis. 1997;25(suppl 2):S206-S210.
39. Bolton RP, Culshaw MA. Fecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associate colitis due to Clostridium difficile. Gut. 1986;27:1169-1172.
40. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758-764.
41. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:765-767.
42. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for treatment of Clostridium difficile colitis. Dis Colon Rectum. 2001;44:1176-1180.
43. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640-645.
44. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother. 2004;53:882-884.
45. Lipsett PA, Samantaray DK, Tam JL, et al. Pseudomembranous colitis: a surgical disease? Surgery. 1994;116:491-496.
46. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149-154.
47. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620-1626.
48. Bartlett JG. Treatment of Clostridium difficile colitis. Gastroenterology. 1985;89:1192-1195.
49. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA. 1996;275:870-876.
50. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ. 2005;173:167-170.
51. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
52. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treatment with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
53. Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother. 2006;40:2164-2169.
54. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis. 2006;43:428-431.
55. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis. 2006;43:411-420.